Journey Medical Corporation (DERM)
- Previous Close
6.88 - Open
6.92 - Bid 6.70 x 100
- Ask 7.07 x 100
- Day's Range
6.81 - 7.04 - 52 Week Range
3.20 - 7.84 - Volume
96,365 - Avg. Volume
76,267 - Market Cap (intraday)
159.072M - Beta (5Y Monthly) 0.87
- PE Ratio (TTM)
-- - EPS (TTM)
-0.72 - Earnings Date May 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.88
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
journeymedicalcorp.com41
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: DERM
View MorePerformance Overview: DERM
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DERM
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DERM
View MoreValuation Measures
Market Cap
159.07M
Enterprise Value
163.85M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.50
Price/Book (mrq)
7.93
Enterprise Value/Revenue
2.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.14%
Return on Assets (ttm)
-10.88%
Return on Equity (ttm)
-72.60%
Revenue (ttm)
56.13M
Net Income Avi to Common (ttm)
-14.67M
Diluted EPS (ttm)
-0.72
Balance Sheet and Cash Flow
Total Cash (mrq)
20.3M
Total Debt/Equity (mrq)
128.08%
Levered Free Cash Flow (ttm)
-18.57M